$IRWD News

Ironwood Pharma Says FDA Approves Use Of LINZESS In Pediatric Patients 2 Years Of Age And Older With Functional Constipation

Ironwood Pharmaceuticals: A Contrarian Buy Opportunity

Ironwood Pharmaceuticals, Inc: Still A Profitable Opportunity

Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due

Ironwood Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Ironwood Pharmaceuticals (NASDAQ:IRWD) Crushes Q1 Estimates with 97% LINZESS Surge

Ironwood Pharmaceuticals Affirms FY2026 Sales Guidance of $450.000M-$475.000M vs $458.593M Est

Ironwood Pharmaceuticals Q1 Adj. EPS $0.24, Inline, Sales $106.506M Beat $92.088M Estimate

Ironwood Pharmaceuticals Presents New Findings From Survey Assessing Healthcare Provider Perspectives On The Use Of Total Parenteral Nutrition In The Treatment Of Short Bowel Syndrome

Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why

Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance

Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide

Citizens Maintains Market Outperform on Ironwood Pharmaceuticals, Raises Price Target to $10

Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highlights: Strong LINZESS Sales and ...

Ironwood Pharmaceuticals Q4 Earnings Call Highlights

Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Ironwood Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation